申请人:Pfizer Inc.
公开号:US04898872A1
公开(公告)日:1990-02-06
A series of novel heterobicyclic substituted 2-(1H)-quinolone compounds have been prepared, including the 3,4-dihydro derivatives thereof, wherein the heterobicyclic ring moiety is an optionally-substituted indolyl, phthalizinyl, benzimidazolyl, imidazopyridinyl, quinolinyl or isoquinolinyl group attached by an nitrogen or carbon atom of said group to the 6-position of the quinolone ring. The optional substituent is a C.sub.1 -C.sub.14 alkyl group located on either of the two heterobicyclic rings and/or an oxo group situated on the heterocyclic portion of said heterobicyclic ring system. These particular compounds are useful in therapy as cardiac stimulants and therefore, are of value in the treatment of various cardiac conditions. 6-1(H)-Imidazo[4,5-b]pyridin-6-yl}-8-methyl-2-(1H)-quinolone represents a typical and preferred member compound. Methods for preparing these compounds from known starting materials are provided.
一系列新型杂双环取代的2-(1H)-喹啉化合物已经制备出来,包括其3,4-二氢衍生物,其中,该杂双环环基是一个可选取代的吲哚基、菲嗪基、苯并咪唑基、咪唑吡啶基、喹啉基或异喹啉基,通过该基的氮或碳原子连接到喹啉环的6位。可选的取代基是位于两个杂双环环上的C.sub.1-C.sub.14烷基和/或位于该杂双环环系统的杂环部分上的氧代基。这些特定化合物在治疗心脏刺激剂方面是有用的,因此在治疗各种心脏疾病方面具有价值。6-1(H)-咪唑并[4,5-b]吡啶-6-基}-8-甲基-2-(1H)-喹啉代表了一种典型和优选的成员化合物。提供了从已知起始材料制备这些化合物的方法。